Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
Sponsored By: Representative Rep. Roy, Chip [R-TX-21]
Introduced
Summary
Creates a pathway for U.S. approval of drugs, biologics, and devices already lawfully marketed abroad. It would set eligibility rules, require sponsors to submit translated foreign dossiers, impose a 30-day decision clock, and allow congressional disapproval.
Show full summary
- Patients and families: Could speed access to treatments and devices that address a public health or unmet medical need and are not currently available in the U.S.
- Sponsors and manufacturers: Would file a request with English translations of foreign dossiers and pay applicable fees as if filing an application. The agency would approve or deny within 30 days and could require postmarket studies or risk-mitigation plans.
- FDA and Congress: The agency may deny approvals for safety or effectiveness and must report denials monthly to congressional committees. Congress could block an approval through a joint resolution.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Faster U.S. access to foreign-approved treatments
If enacted, the bill would set up a fast track for some medicines and devices already sold abroad. A company could ask the FDA to recognize a drug, biologic, or device that is lawfully marketed in countries named in law or in the United Kingdom. It would only apply if the product is not already cleared in the United States, has not been pulled abroad for safety or effectiveness, is not a banned device, and meets a public health or unmet medical need here. The FDA would have 30 days to grant or deny; it could require extra safety studies or risk controls, and labeling would be set during that window. The order would take effect unless Congress overturns it under fast‑track rules, and the FDA would report denials to Congress.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Rep. Roy, Chip [R-TX-21]
TX • R
Cosponsors
Rep. Harris, Andy [R-MD-1]
MD • R
Sponsored 2/27/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in